SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-066691
Filing Date
2021-03-03
Accepted
2021-03-03 08:16:54
Documents
14
Period of Report
2021-03-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d95393d8k.htm   iXBRL 8-K 24966
2 EX-99.1 d95393dex991.htm EX-99.1 55361
6 GRAPHIC g95393g28p00.jpg GRAPHIC 2903
  Complete submission text file 0001193125-21-066691.txt   217472

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mgta-20210303.xsd EX-101.SCH 3071
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mgta-20210303_lab.xml EX-101.LAB 18121
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mgta-20210303_pre.xml EX-101.PRE 11405
7 EXTRACTED XBRL INSTANCE DOCUMENT d95393d8k_htm.xml XML 3347
Mailing Address 100 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139
Business Address 100 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Magenta Therapeutics, Inc. (Filer) CIK: 0001690585 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38541 | Film No.: 21707276
SIC: 2834 Pharmaceutical Preparations